You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

Peter Linde Biography and Net Worth

Insider of Morphic

Dr. Peter G. Linde M.D. serves as Chief Medical Officer of the Company. He has served as Vice President of medical research at Acceleron Pharma, Inc. since July 2016. Prior to Acceleron, Dr. Linde served as Global Project Leader, Development at AbbVie Inc. from September 2011 to June 2016 and as Senior Director of Clinical Research at FibroGen, Inc. from 2010 to 2011. Prior to this, Dr. Linde served as Co-Founder and President of Triaxis Medical Devices, Inc., a medical device company, from 2008 to 2010. Dr. Linde received his bachelor’s degree in Chemical Engineering and Applied Biology from the Massachusetts Institute of Technology and his Medical Doctorate from Stanford University School of Medicine.

What is Peter Linde's net worth?: The estimated net worth of Peter Linde is at least $163,739.52 as of June 1st, 2021. Dr. Linde owns 5,952 shares of Morphic stock worth more than $163,740 as of April 19th. This net worth estimate does not reflect any other assets that Dr. Linde may own. Learn More about Peter Linde's net worth.
How do I contact Peter Linde?: The corporate mailing address for Dr. Linde and other Morphic executives is 35 Gatehouse Drive A2, Waltham MA, 02451. Morphic can also be reached via phone at (781) 996-0955. Learn More on Peter Linde's contact information.
Has Peter Linde been buying or selling shares of Morphic?: Peter Linde has not been actively trading shares of Morphic over the course of the past ninety days. Most recently, Peter Linde sold 4,000 shares of the business's stock in a transaction on Thursday, September 16th. The shares were sold at an average price of $66.51, for a transaction totalling $266,040.00. Learn More on Peter Linde's trading history.
Who are Morphic's active insiders?: Morphic's insider roster includes Robert Farrell, Jr. (CAO), Peter Linde (Insider), Bruce Rogers (Insider), Marc Schegerin (CFO), and Timothy Springer (Director). Learn More on Morphic's active insiders.
Are insiders buying or selling shares of Morphic?: During the last twelve months, Morphic insiders bought shares 2 times. They purchased a total of 1,052,400 shares worth more than $47,299,440.00. During the last twelve months, insiders at the sold shares 19 times. They sold a total of 217,841 shares worth more than $10,898,821.11. The most recent insider tranaction occured on January, 16th when CEO Praveen P Tipirneni sold 13,923 shares worth more than $382,743.27. Insiders at Morphic own 28.1% of the company. Learn More about insider trades at Morphic.
Information on this page was last updated on 1/16/2024.

Peter Linde Insider Trading History at Morphic

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/16/2021	Sell	4,000	$66.51	$266,040.00
6/1/2021	Sell	6,000	$49.85	$299,100.00	5,952

Peter Linde Buying and Selling Activity at Morphic

Morphic Company Overview

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $27.51

$27.24

$28.13

50 Day Range

MA: $34.38

$27.51

$40.31

2 Week Range

Now: $27.51

$19.34

$63.08

Volume

369,158 shs

Average Volume

507,409 shs

Market Capitalization

$1.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42